New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
10:51 EDTAPRIApricus Biosciences upgraded to Buy from Hold at Cantor
Cantor Fitzgerald upgraded Apricus Biosciences to Buy citing potential upcoming pipeline catalysts. The firm raised its price target for shares to $3 from $2.50.
News For APRI From The Last 14 Days
Check below for free stories on APRI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:35 EDTAPRIApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 12, 2014
07:28 EDTAPRIApricus Biosciences files $100M mixed securities shelf
Subscribe for More Information
07:07 EDTAPRIAspire Capital purchases 1.16M shares of Apricus Biosciences for $2M
Subscribe for More Information
07:05 EDTAPRIApricus Biosciences reports Q2 EPS 5c, consensus (4c)
Reports Q2 revenue $5.5M, consensus $5.45M.
August 8, 2014
07:36 EDTAPRIApricus Biosciences announces multi-year partnership with SRF
Apricus Biosciences announced a multi-year partnership agreement with the Scleroderma Research Foundation, or SRF, to support the foundation's activities and the further progress of SRF's groundbreaking research programs. As part of the partnership, Apricus will co-sponsor an upcoming Scleroderma Research Roundtable Series and plans to participate in SRF's Annual Scientific Workshop and an SRF-sponsored event to take place at the upcoming American College of Rheumatology 2014 Annual Meeting. Apricus' product candidate for the treatment of Raynaud's phenomenon, RayVa, is expected to begin a phase 2a clinical trial in the second half of 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use